What are the characteristics of ARGENX SE stock?

ARGENX SE is a company operating in the Biotechnologies sector. The stock is listed on Euronext Brussels under ISIN NL0010832176.

What is the recent price evolution of ARGENX SE stock?

Since last close: -0.41 %. Over one week: 4.99 %. Over one year: 7.61 %.

Argenx to Participate in Two Major Investor Conferences in the US this June

Belgian biotech company Argenx announced on Wednesday its participation in two major investor conferences in the United States in June. Members of its management will present the group's strategy and activities, specializing in immunology.

Published on May 27, 2026 at 10:29

Argenx to Participate in Two Major Investor Conferences in the US this June

ARGENX SE

783.40 € -0.41 %

Add us as a preferred source on Google

Two Scheduled Presentations in June

Argenx will participate in the William Blair 46th Annual Growth Stock Conference, with a presentation scheduled for Wednesday, June 3 at 12:40 PM Central Time in Chicago. The company will also be represented at the Goldman Sachs 47th Annual Global Healthcare Conference by a fireside chat on Tuesday, June 9 at 4:00 PM Eastern Time in Miami. The presentations will be available live via a webcast from the Investors section of the argenx.com/investors website. A replay will remain available on the website for about 30 days following each presentation.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ UCB share price breaks through €219 and surges nearly 12% following raised targets 🗞️ Nanobiotix share declines 1% but posts +22% on the week 🗞️ Abivax stock drops 30% over the quarter and turns red again 🗞️ Valneva stock breaks below its €2.42 support level and continues to decline

Context

Period

Period: 9M 2026

Key reported figures

Revenue: 4 605 millions de dollars
Quarterly revenue: 4 605 millions de dollars
Revenue growth: 57,4 %
Net income: 1 344 millions de dollars

Guidance from the release

argenx remains on track to achieve its 'Vision 2030' anchored in the ambition to treat 50,000 patients globally

Risks mentioned

The risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials
Demand and commercialization risks for argenx's products and product candidates, including new indications
Regulatory and pricing uncertainties for argenx's products and product candidates if approved

Opportunities identified

Vision 2030 targets: treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates
Multiple label and indication expansions for VYVGART being pursued across additional autoimmune diseases
Next-generation FcRn molecules (ARGX-213 Phase 3-ready, ARGX-124 in Phase 1) advancing through development

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Two Scheduled Presentations in June

Context

Also read